Neohepatect (Human Hepatitis B Immunoglobulin)

Human Hepatitis B Immunoglobulin, the active ingredient in Neohepatect, is an immunoglobulin presented as a sterile solution for intravenous use. It provides passive immunity to individuals at risk of hepatitis B virus infection, such as newborns of hepatitis B‑positive mothers, patients undergoing liver transplantation, or those requiring post‑exposure prophylaxis.

GNH USA supplies Neohepatect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology units and pharmacies worldwide, ensuring quality and regulatory compliance across markets and reliable delivery to patients.

Neohepatect, a human hepatitis B immunoglobulin, provides passive immunity against hepatitis B virus infection.

- Prevention of mother‑to‑child transmission: administered to newborns of hepatitis B‑positive mothers to reduce the risk of early infection. - Post‑exposure prophylaxis: given to individuals after potential hepatitis B exposure to provide immediate passive antibodies until active immunity develops. - Pre‑transplant prophylaxis: used in liver transplant candidates and recipients to prevent hepatitis B infection or reactivation during the peri‑operative period. - Immunocompromised patient protection: administered to patients with weakened immune systems who are at heightened risk of hepatitis B infection.

Human hepatitis B immunoglobulin may be associated with the following adverse reactions.

Common Side Effects: - Fever: mild to moderate temperature elevation. - Headache: transient headache reported. - Nausea: occasional nausea or upset stomach. - Injection site reactions: redness, swelling, or discomfort at the infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thrombosis: rare occurrence of blood clot formation. - Renal dysfunction: possible acute kidney injury in susceptible patients.

When using Neohepatect, consider the following precautions to ensure safe administration.

- Allergy assessment: verify no known hypersensitivity to human immunoglobulins or blood products. - Renal function: monitor kidney function in patients with pre‑existing renal impairment. - Pregnancy and lactation: weigh potential benefits against unknown risks; use only if clearly indicated. - Concurrent immunoglobulin therapy: avoid overlapping doses to prevent excess volume load. - Thrombotic risk: assess for history of clotting disorders before infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human hepatitis B immunoglobulin can interact with certain medications and vaccines.

Major Interactions (Avoid): - Live vaccines: concurrent administration may reduce vaccine efficacy; postpone live vaccines for at least 3 months. - Immunosuppressants: high‑dose immunoglobulin may augment immunosuppressive effects, increasing infection risk.

Moderate Interactions (Monitor Closely): - Anticoagulants: may enhance anticoagulant effect, monitor coagulation parameters. - Blood pressure agents: volume load from infusion can affect blood pressure; observe patients with hypertension. - Other immunoglobulins: concurrent use may increase risk of hyperviscosity; monitor serum viscosity.